Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma

13 Aug 2025

Abstract excerpt

PURPOSE Large B-cell lymphomas (LBCLs) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA) as minimal residual disease (MRD) may improve the determination of remission. METHODS We integrated data from five prospective studies of frontline anthracycline-based chemotherapy in patients with LBCL....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to CNS Lymphoma Diagnosis and Treatment
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40802906
DOI: 10.1200/jco-25-01534

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Remission Assessment by Circulating Tumor DNA in Large B-Cell LymphomaPMID 40802906Read ↗

Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphomaSemantic proximity Read ↗

Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature ReviewSemantic proximity Read ↗

Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient ManagementSemantic proximity Read ↗

Clinical implications of circulating tumor DNA in predicting the outcome of first line treatment in diffuse large B-cell lymphoma (DLBCL) patientsSemantic proximity Read ↗

Analytical Validation of a Circulating Tumor DNA Assay using PhasED-Seq Technology for Detecting Residual Disease in B-Cell MalignanciesSemantic proximity Read ↗

Circulating tumour DNA in B‐cell lymphomas: current state and future prospectsSemantic proximity Read ↗

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas.Semantic proximity Read ↗

Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.Semantic proximity Read ↗

Prognostic and Therapeutic Implications of Measurable Residual Disease Detection Across Hematologic Malignancies: Clinical Impact on Relapse Prediction and Survival OutcomesSemantic proximity Read ↗

The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell LymphomaSemantic proximity Read ↗

Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual DiseaseSemantic proximity Read ↗

Circulating Tumor DNA Assessment in Classic Hodgkin Lymphoma: Ready for Primetime?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.